- PPTI Announces New Web Site Launch -
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Protein Polymer Technologies
(OTC Bulletin Board: PPTI), a Company focused on development of high
performance bio-active devices designed for improved surgical outcomes,
announced today that it has retained The Ruth Group as its investor relations
and financial communications agency. The Ruth Group will counsel management
on the development and implementation of its strategic investor relations
program. Separately, Protein Polymer Technologies announced the launch of its
newly redesigned web site effective today ( http://www.ppti.com ).
"We are pleased to announce The Ruth Group as our strategic financial
communications partner," said J. Thomas Parameter, President and CEO of
Protein Polymer Technologies. "The Ruth Group has extensive experience in the
healthcare sector and in helping companies create proactive investor relations
programs to communicate with existing and potential shareholders and to build
visibility of companies like Protein Polymer. Given the increasing interest
in advanced biomaterials technology and bio-active medical products, our new
Web site represents a key part of PPTI's program to raise the Company's
visibility in the investment community."
About The Ruth Group
Ranked as one of the top U.S. financial IR/PR agencies in 2001 and 2002,
The Ruth Group, based in New York, focuses on serving the communications needs
of business services, healthcare, biotechnology, financial services,
semiconductor, and technology companies. Services include investor relations,
public relations, management counsel, corporate positioning, pre-IPO public
relations programs, media relations and venture capital relations.
About Protein Polymer Technologies
Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing bioactive devices to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, creating an extensive portfolio of proprietary biomaterials for use
in the development of bioactive devices. These genetically engineered
biomaterials are high molecular weight proteins, processed into products with
physical and biological characteristics tailored to specific clinical
performance requirements. Targeted products include urethral bulking agents
for the treatment of stress urinary incontinence, dermal augmentation products
for cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery. To date, PPTI has been issued twenty-five U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.
Safe Harbor
This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer
to the Company's 2002 Annual Report Form 10-KSB, and other recent filings with
the Securities and Exchange Commission, copies of which are available from the
Company, to further ascertain the risks associated with the above statements.
SOURCE Protein Polymer Technologies, Inc.
 back to top
Related links:
http://www.ppti.com
CONTACT:
J. Thomas Parmeter, Ph.D., President, Chief
Executive Officer of Protein Polymer Technologies, Inc.,
+1-858-558-6064; or investors, Jill Meleski, Assistant Vice
President of The Ruth Group, +1-646-536-7032, for Protein Polymer
Technologies, Inc.
|
